💥 UTRxMYCN M1-14 has been granted dual @fda.gov designations for sarcomas based on preclinical data, moving the treatment closer to helping address unmet needs.

Read more here 📰: onclive.com/view/utrxmyc...

#scmsm #oncology

📝 @fda.gov approvals in ccRCC and CCA, orphan drug and fast track designations in sarcoma, and a priority review in bladder cancer?

Test your knowledge with this week's news quiz: onclive.com/view/onclive...

#oncology #blcsm #kcsm #scmsm

💥 The @fda.gov has granted orphan drug designation to SOT106 in STS in addition to a fast track designation in osteosarcoma, giving the ADC dual designations for both sarcoma subtypes.

Full details 📈: www.onclive.com/view/sot106-...

#scmsm #oncology